The Latest Breaking News from FDA

Today's 5 Stock Ideas: Ra Medical Systems (RMED) - Shares up 55.5% premarket. The company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter. Rubicon Technology (RBCN) - Shares up

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Discreet and available by mail, abortion-inducing pills could make conservative abortion bans challenging to enforce.

Time for a new Operation Warp Speed?

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S.

The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022. The panel has advised manufacturers to develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a…

Senators asked for an investigation since the "sweet, chocolaty taste may encourage consumers to eat well over a recommended quantity of melatonin."